April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
In Vitro and In Vivo Tolerance and Transfection Efficiency in Ocular Surface Structures of New Nanoparticles Loaded with a MUC5AC Coding Plasmid
Laura Contreras-Ruiz; Giovanni K. Zorzi; Jenny E. Párraga; Karyn F. Siemasko; Denis Hileeto; Margarita Calonge; Michael E. Stern; Begoña Seijo; Alejandro Sánchez; Yolanda Diebold
Author Affiliations & Notes
  • Laura Contreras-Ruiz
    Ocular Surface Group, IOBA - University of Valladolid, Valladolid, Spain
    Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Valladolid, Spain
  • Giovanni K. Zorzi
    Department of Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Santiago de Compostela, Spain
  • Jenny E. Párraga
    Department of Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Santiago de Compostela, Spain
  • Karyn F. Siemasko
    Biological Sciences, Allergan, Inc, Irvine, California
  • Denis Hileeto
    Ocular Surface Group, IOBA - University of Valladolid, Valladolid, Spain
  • Margarita Calonge
    Ocular Surface Group, IOBA - University of Valladolid, Valladolid, Spain
    Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Valladolid, Spain
  • Michael E. Stern
    Biological Sciences, Allergan, Inc, Irvine, California
  • Begoña Seijo
    Department of Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Santiago de Compostela, Spain
  • Alejandro Sánchez
    Department of Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Santiago de Compostela, Spain
  • Yolanda Diebold
    Ocular Surface Group, IOBA - University of Valladolid, Valladolid, Spain
    Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Valladolid, Spain
  • Footnotes
    Commercial Relationships  Laura Contreras-Ruiz, None; Giovanni K. Zorzi, None; Jenny E. Párraga, None; Karyn F. Siemasko, Allergan Inc., CA (USA) (F); Denis Hileeto, None; Margarita Calonge, Allergan Inc., CA (USA) (C); Michael E. Stern, Allergan Inc., CA (USA) (F); Begoña Seijo, None; Alejandro Sánchez, None; Yolanda Diebold, None
  • Footnotes
    Support  MAT2007-64626-C02-01/02 (Ministry of Science), FPU and FPI Scholarship Programs (Ministry of Education), and CIBER-BBN (Ministry of Health), Spain; Program AlBan E07D402978BR (EU)
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 420. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      In Vitro and In Vivo Tolerance and Transfection Efficiency in Ocular Surface Structures of New Nanoparticles Loaded with a MUC5AC Coding Plasmid
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Laura Contreras-Ruiz, Giovanni K. Zorzi, Jenny E. Párraga, Karyn F. Siemasko, Denis Hileeto, Margarita Calonge, Michael E. Stern, Begoña Seijo, Alejandro Sánchez, Yolanda Diebold; In Vitro and In Vivo Tolerance and Transfection Efficiency in Ocular Surface Structures of New Nanoparticles Loaded with a MUC5AC Coding Plasmid. Invest. Ophthalmol. Vis. Sci. 2011;52(14):420.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To evaluate the in vitro and in vivo tolerance and transfection efficiency in ocular surface structures of a new nanoparticle system loaded with a plasmid coding for a modified MUC5AC protein (pMUC5AC).

Methods: : Cationized gelatin and chrondroitin sulfate-based nanoparticles (NPs) were prepared by ionotropic gelation and loaded with pMUC5AC (P201031678). Epithelial cell lines from human cornea and conjunctiva were exposed to NPs for 3h. Toxicity and MUC5AC expression were evaluated after 72h by XTT, ELISA and real time RT-PCR (RT2-PCR). In vivo tolerance and transfection efficiency was studied in C57BL/6 mice. 5µl of naked plasmid, blank NPs or pMUC5AC-NPs were instilled in both eyes 4 times/day for 3 or 5 days. Control animals received no instillations. Clinical signs, corneal fluorescein staining and tear production were evaluated before and after treatment. MUC5AC expression was quantified by RT2-PCR. Ocular structures were processed for pathology study. Two-way ANOVA was done for statistical analysis.

Results: : There was no significant difference in cell viability between control and NP-exposed cells. Expression of modified MUC5AC was detected in both cell lines exposed to pMUC5AC-NPs. Neither ocular discomfort nor irritation was observed in vivo after pMUC5AC-NP treatment. pMUC5AC-NPs had no significant effect on fluorescein staining or tear production. After treatment, MUC5AC expression from the plasmid was detected in conjunctiva, but not in cornea. Ocular surface of treated mice showed normal morphology with a complete lack of inflammatory changes.

Conclusions: : pMUC5AC-NPs were well tolerated, and induced the expression of modified MUC5AC in ocular surface structures, both in vitro and in vivo. This work is a proof-of-concept of the potential therapeutic application of a newly developed nanomedicine treatment modality.

Keywords: cornea: epithelium • gene transfer/gene therapy • inflammation 
© 2011, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept